National Health and Family Planning Commission publishes 17 new drug priority review lists

Source: on September 15, 2015, the national health and Family Planning Commission publicized the drug varieties to be recommended for priority review on major new drug creation science and technology major projects In order to accelerate the output process of major new drug creation science and technology major projects, the national health and Family Planning Commission of the people's Republic of China proposed to recommend ct-707, etc Drug varieties with special support are the priority ones Now the varieties to be recommended are publicized The publicity time is from September 14, 2015 to September 25, 2015 If you have any objection, please give it back to me Tel: 010-68791854 Fax: 010-68792226 mail box: yxsp_zdzx@163.com address: Room 501, welcome building, national health and Family Planning Commission office area, Friendship Hotel, No 1 South Zhongguancun Street, Haidian District, Beijing, 100873 Appendix: list of priority drugs to be recommended for new drug special project Docx major new drug creation technology major project implementation management office September 14, 2015, list of priority drugs to be recommended for new drug special project serial number, variety name, R & D unit expert opinion 1 ct-707 clinical application Beijing sailintai Pharmaceutical Technology Co., Ltd recommends 2 fubitavir for clinical application, Sichuan University, Changzhou Yinsheng Pharmaceutical Co., Ltd recommends 3 pyrrolidine maleate for clinical application, Jiangsu Hengrui Pharmaceutical Co., Ltd recommends 4 niketinib and 4 tablets for clinical application Guangzhou Institute of biomedicine and health, Chinese Academy of Sciences and Guangzhou Shunjian Biomedical Technology Co., Ltd recommend 5 ximingpirui for clinical application, Shanghai Institute of pharmaceutical, Chinese Academy of Sciences recommend 6 antibacterial peptide pl-5 for clinical application, Changchun Pulai Pharmaceutical Biotechnology Co., Ltd recommend 7 Application for clinical application of miplatin for injection Jiangsu aosaikang Pharmaceutical Co., Ltd recommends 8 recombined human albumin application for clinical application Zhejiang Haizheng Pharmaceutical Co., Ltd recommends 9 recombined human anti-PD-1 monoclonal antibody injection application for clinical application Shanghai Junshi Biomedical Technology Co., Ltd It is recommended to recommend 10 recombinant human anti-HER2 monoclonal antibody for injection to apply for clinical application It is recommended to recommend 11 recombinant anti-HER2 domain Ⅱ human monoclonal antibody for injection to apply for clinical application It is recommended to recommend 12 Application for clinical application of recombinant anti epidermal growth factor receptor humanized monoclonal antibody injection Recommendation of 15 chlorofarabine injection for production of Qilu Pharmaceutical Co., Ltd recommendation of 16 conbercept ophthalmic injection for production of Chengdu Kanghong Biotechnology Co., Ltd recommendation of 17 olantiweikang tablets for production of Jiangxi Qingfeng Pharmaceutical Co., Ltd